NUVISAN is offering world-leading expertise and capabilities to develop the optimal assays for your target, run the screening campaign in ultra-high-throughput and follow up the hits in lead optimization until the clinical candidate compound is identified.
Our portfolio contains biochemical, biophysical as well as cell- and phenotypic-based HTS compatible assay technologies.
NUVISAN has over 20 years of experience in designing screening campaigns to reliably identify the most effective and selective compounds for your target. The flexible setup of our automated liquid handling and uHTS systems (>150,000 datapoints per day) allow us to run several screening campaigns in parallel and to adapt the workflows to your project needs.
NUVISAN can screen your compound library, but we have also access more than 3 million well-characterized compounds from Bayer's library to fuel your lead identification project's success. Our screening and medicinal chemists collaboratively evaluate the hit list to select the most promising candidates.
We possess several High-Content Screening setups based on poly-automated confocal Opera Phenix systems as well as brightfield microscopes to support 2d, 3d and 4d cellular assays and screening campaigns. Poly-automated cell cultivation and liquid handling stations enhance our throughput capabilities. Our powerful IT infrastructure supports multiparametric image analysis and artificial intelligence-based evaluation strategies.
NUVISAN supports hit-to-lead and lead optimization programs with a wide range of methods for compound characterization. Our very fast turnaround times of around one week from compound delivery to data report pave the way towards effective decision making based on comprehensive data sets in lead optimization cycles.
Moreover we have developed during the last 20 years profound knowledge in high-throughput binding kinetic characterization, mode of action studies, protein degradation assays, Schild analysis, selectivity assessment and orthologs assays.